Taken together, these results show the anti-inflammatory effects of inhibiting VAP-1/SSAO enzymatic function and highlight the potential of PXS-4728A as a novel therapeutic tool in diseases that are characterized by a neutrophilic pattern of inflammation, including acute lung injury, chronic obstructive pulmonary disease, cystic fibrosis, and bronchiolitis obliterans syndrome. Here, AOC2 is linked to chronic obstructive pulmonary disease.